A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
Overall venture investment in the sector remains steady, but the big strategics back off.
The group has finally revalued its troubled sleep franchise. So what now?
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.